Hannah Clarke

"It's certainly a bigger problem with advancing age in the geriatric population, and it can be a tremendous source of cost for patients who have these issues," says Gina M. Rooker, MD.

Men of African ancestry were less likely to be treated on clinical trials after undergoing comprehensive genomic profiling compared with men of European ancestry.

The investigators found that patients who experienced recurrence following BCG therapy were more likely to have BRS3 tumors compared with BRS1 or BRS2.

"From a LUGPA vantage point, we are extremely excited to see the significant congressional attention to PBMs," says Mara R. Holton, MD.

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.

"We believe that more thorough body weight control in childhood could serve as a preventive measure for preserving testicular function in adulthood," says Rosella Cannarella, MD, PhD.

"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.

The trial assessed outcomes in patients who had kidney stones between 1 to 2 cm.

Trajectory inference analysis pointed to SIX2+CITED1+ as the nephrogenic cancer stem cells at the origin of Wilms tumor.

“These results validate the clinical value of bone biomarker assessment in the HSPC state," state the authors.

The findings held even when the investigators adjusted for age, past medical history, smoking status, and type of surgery.

The study also found a positive correlation between burnout and discrimination-based trauma in trainees.

In the study, 69% of patients who underwent complete ablation had no visible disease at first endoscopic evaluation, compared with 40% of patients who underwent chemoablation therapy.

Of all malignant bladder cancer lesions, 28% were only identified with blue light.

Patients who underwent sacrocolpopexy and were discharged on post-op day 0 had fewer instances of readmissions and fewer high-grade (class III-IV) complications.

"This institute model will lower barriers for access to some of the highest quality care in the world,” says Alexander Kutikov, MD, FACS.

"What was great about this partnership is we recognized that this is going to be the future of medicine at some point, and we want to be able to be a part of that cutting edge technology," says Nitin K. Yerram, MD.

Optimal bedtime was determined using the bedtime and mid-awake time for each patient, which was gathered from an Actiwatch Spectrum device.

In this installment, Suzanne B. Merrill, MD, FACS, and Dan Humer, PA-C, highlight Colorado Urology, a Denver-based practice within the United Urology group.

"In summary, it was safe and effective. There [were] no serious adverse events...and the vast majority of patients received no anesthesia with very similar results to shock wave lithotripsy,” said Ben H. Chew, MD, MSc, FRCSC.

"It is unique given that in addition to providing prognostic information, it can serve as a marker to predict sensitivity to androgen deprivation therapy (ADT), which is the backbone of systemic therapy for men with prostate cancer," says Rana R. McKay, MD.

The tool uses clinical covariates to predict changes in storage, voiding, and nocturia LUTS for patients receiving placebo, dutasteride, tamsulosin, or DUT/TAM combination therapy.

"Proxies for social determinants of health that we found to be associated with higher overall mortality included living in a more deprived area, as well as having Medicaid or Medicare insurance," says David Miller, MD.

In the ARASTEP trial, the primary outcome measure of rPFS is being measured by PSMA-PET/CT imaging with 68Ga-PSMA-11 (prepared using Illuccix) or piflufolastat F 18.

The methylation-based urine test is performed on a qPCR platform and is intended for use in conjunction with cystoscopy.

"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.

“The results of the study imply that UGN-101 is not only a renal-preserving therapy for UTUC in this comorbid population, but could potentially delay the time to dialysis or radical nephroureterectomy," says Kyle M. Rose, MD.

"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.

The guideline updates span non-metastatic upper tract urothelial carcinoma, female stress urinary incontinence, urethral stricture disease, and prostate cancer.